Faderl S, Talpaz M, Estrov Z, Kantarjian HM. Chronic myelogenous leukemia: biology and therapy. Ann Intern Med. 1999;131:207–19.

Article  CAS  PubMed  Google Scholar 

Wohrle FU, Daly RJ, Brummer T. Function, regulation and pathological roles of the Gab/DOS docking proteins. Cell Commun Signal. 2009;7:22.

Article  PubMed  PubMed Central  Google Scholar 

Pendergast AM, Quilliam LA, Cripe LD, Bassing CH, Dai Z, Li N, et al. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell. 1993;75:175–85.

Article  CAS  PubMed  Google Scholar 

Arnaud M, Crouin C, Deon C, Loyaux D, Bertoglio J. Phosphorylation of Grb2-associated binder 2 on serine 623 by ERK MAPK regulates its association with the phosphatase SHP-2 and decreases STAT5 activation. J Immunol. 2004;173:3962–71.

Article  CAS  PubMed  Google Scholar 

Adams SJ, Aydin IT, Celebi JT. GAB2-a scaffolding protein in cancer. Mol Cancer Res. 2012;10:1265–70.

Article  CAS  PubMed  Google Scholar 

Wada T, Nakashima T, Oliveira-dos-Santos AJ, Gasser J, Hara H, Schett G, et al. The molecular scaffold Gab2 is a crucial component of RANK signaling and osteoclastogenesis. Nat Med. 2005;11:394–9.

Article  CAS  PubMed  Google Scholar 

Sies K, Spohr C, Grunder A, Todorova R, Uhl FM, Huber J, et al. Gab2 is essential for transformation by FLT3-ITD in acute myeloid leukemia. Hemasphere. 2019;3:e184.

Article  PubMed  PubMed Central  Google Scholar 

Spohr C, Poggio T, Andrieux G, Schonberger K, Cabezas-Wallscheid N, Boerries M, et al. Gab2 deficiency prevents Flt3-ITD driven acute myeloid leukemia in vivo. Leukemia. 2022;36:970–82.

Article  CAS  PubMed  Google Scholar 

Halbach S, Hu Z, Gretzmeier C, Ellermann J, Wohrle FU, Dengjel J, et al. Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells. Cell Commun Signal. 2016;14:6.

Article  PubMed  PubMed Central  Google Scholar 

Halbach S, Kohler M, Uhl FM, Huber J, Zeiser R, Koschmieder S, et al. Gab2 is essential for Bcr-Abl-mediated leukemic transformation and hydronephrosis in a chronic myeloid leukemia mouse model. Leukemia. 2016;30:1942–5.

Article  CAS  PubMed  Google Scholar 

Halbach S, Rigbolt KT, Wohrle FU, Diedrich B, Gretzmeier C, Brummer T, et al. Alterations of Gab2 signalling complexes in imatinib and dasatinib treated chronic myeloid leukaemia cells. Cell Commun Signal. 2013;11:30.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wohrle FU, Halbach S, Aumann K, Schwemmers S, Braun S, Auberger P, et al. Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors. Leukemia. 2013;27:118–29.

Article  CAS  PubMed  Google Scholar 

Aumann K, Lassmann S, Schopflin A, May AM, Wohrle FU, Zeiser R, et al. The immunohistochemical staining pattern of Gab2 correlates with distinct stages of chronic myeloid leukemia. Hum Pathol. 2011;42:719–26.

Article  CAS  PubMed  Google Scholar 

Koschmieder S, Gottgens B, Zhang P, Iwasaki-Arai J, Akashi K, Kutok JL, et al. Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis. Blood. 2005;105:324–34.

Article  CAS  PubMed  Google Scholar 

Nishida K, Wang L, Morii E, Park SJ, Narimatsu M, Itoh S, et al. Requirement of Gab2 for mast cell development and KitL/c-Kit signaling. Blood. 2002;99:1866–9.

Article  PubMed  Google Scholar 

Theoharides TC, Valent P, Akin C. Mast cells, mastocytosis, and related disorders. N. Engl J Med. 2015;373:163–72.

Article  CAS  PubMed  Google Scholar 

Varricchi G, Galdiero MR, Loffredo S, Marone G, Iannone R, Marone G, et al. Are mast cells MASTers in cancer? Front Immunol. 2017;8:424.

Article  PubMed  PubMed Central  Google Scholar 

Cerny-Reiterer S, Rabenhorst A, Stefanzl G, Herndlhofer S, Hoermann G, Mullauer L, et al. Long-term treatment with imatinib results in profound mast cell deficiency in Ph+ chronic myeloid leukemia. Oncotarget. 2015;6:3071–84.

Article  PubMed  Google Scholar 

Askmyr M, Agerstam H, Lilljebjorn H, Hansen N, Karlsson C, von Palffy S, et al. Modeling chronic myeloid leukemia in immunodeficient mice reveals expansion of aberrant mast cells and accumulation of pre-B cells. Blood Cancer J. 2014;4:e269.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Arinobu Y, Iwasaki H, Gurish MF, Mizuno S, Shigematsu H, Ozawa H, et al. Developmental checkpoints of the basophil/mast cell lineages in adult murine hematopoiesis. Proc Natl Acad Sci USA. 2005;102:18105–10.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Valent P, Horny HP, Arock M. The underestimated role of basophils in Ph(+) chronic myeloid leukaemia. Eur J Clin Invest. 2018;48:e13000.

Article  PubMed  PubMed Central  Google Scholar 

Feyerabend TB, Weiser A, Tietz A, Stassen M, Harris N, Kopf M, et al. Cre-mediated cell ablation contests mast cell contribution in models of antibody- and T cell-mediated autoimmunity. Immunity. 2011;35:832–44.

Article  CAS  PubMed  Google Scholar 

Brummer T, Larance M, Herrera Abreu MT, Lyons RJ, Timpson P, Emmerich CH, et al. Phosphorylation-dependent binding of 14-3-3 terminates signalling by the Gab2 docking protein. EMBO J. 2008;27:2305–16.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Camacho V, Kuznetsova V, Welner RS. Inflammatory cytokines shape an altered immune response during myeloid malignancies. Front Immunol. 2021;12:772408.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang J, Adrian FJ, Jahnke W, Cowan-Jacob SW, Li AG, Iacob RE, et al. Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature. 2010;463:501–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shelburne CP, McCoy ME, Piekorz R, Sexl V, Roh KH, Jacobs-Helber SM, et al. Stat5 expression is critical for mast cell development and survival. Blood. 2003;102:1290–7.

Article  CAS  PubMed  Google Scholar 

Elefanty AG, Cory S. Hematologic disease induced in BALB/c mice by a bcr-abl retrovirus is influenced by the infection conditions. Mol Cell Biol. 1992;12:1755–63.

CAS  PubMed  PubMed Central  Google Scholar 

Elefanty AG, Hariharan IK, Cory S. bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice. EMBO J. 1990;9:1069–78.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dazzi F, Hasserjian R, Gordon MY, Boecklin F, Cotter F, Corbo M, et al. Normal and chronic phase CML hematopoietic cells repopulate NOD/SCID bone marrow with different kinetics and cell lineage representation. Hematol J. 2000;1:307–15.

Article  CAS  PubMed  Google Scholar 

Kishi K. A new leukemia cell line with Philadelphia chromosome characterized as basophil precursors. Leuk Res. 1985;9:381–90.

Article  CAS  PubMed  Google Scholar 

Yang Y, Li L, Wong GW, Krilis SA, Madhusudhan MS, Sali A, et al. RasGRP4, a new mast cell-restricted Ras guanine nucleotide-releasing protein with calcium- and diacylglycerol-binding motifs. Identification of defective variants of this signaling protein in asthma, mastocytosis, and mast cell leukemia patients and demonstration of the importance of RasGRP4 in mast cell development and function. J Biol Chem. 2002;277:25756–74.

Article  CAS  PubMed  Google Scholar 

Gu H, Saito K, Klaman LD, Shen J, Fleming T, Wang Y, et al. Essential role for Gab2 in the allergic response. Nature. 2001;412:186–90.

Article  CAS  PubMed  Google Scholar 

Steelman LS, Franklin RA, Abrams SL, Chappell W, Kempf CR, Basecke J, et al. Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. Leukemia. 2011;25:1080–94.

Article  CAS  PubMed  Google Scholar 

Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, et al. Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood. 1984;63:789–99.

Article  CAS  PubMed  Google Scholar 

Koschmieder S, Schemionek M. Mouse models as tools to understand and study BCR-ABL1 diseases. Am J Blood Res. 2011;1:65–75.

CAS  PubMed  PubMed Central  Google Scholar 

Zhang B, Ho YW, Huang Q, Maeda T, Lin A, Lee SU, et al. Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia. Cancer Cell. 2012;21:577–92.